Uy Ear
Stock Analyst at Mizuho
(4.16)
# 409
Out of 5,245 analysts
83
Total ratings
48.08%
Success rate
17.96%
Average return
Main Sectors:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLMD Relmada Therapeutics | Maintains: Outperform | $10 → $19 | $7.04 | +169.89% | 3 | Mar 20, 2026 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $26 → $31 | $16.80 | +84.52% | 10 | Mar 13, 2026 | |
| QURE uniQure | Upgrades: Outperform | $12 → $35 | $24.19 | +44.69% | 8 | Mar 11, 2026 | |
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $37 → $35 | $20.86 | +67.79% | 16 | Mar 2, 2026 | |
| ACAD ACADIA Pharmaceuticals | Upgrades: Outperform | $29 → $35 | $21.10 | +65.88% | 16 | Feb 23, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Neutral | $146 → $175 | $156.70 | +11.68% | 11 | Dec 12, 2025 | |
| EOLS Evolus | Maintains: Outperform | $20 → $19 | $6.09 | +211.99% | 4 | Dec 2, 2025 | |
| ALKS Alkermes | Maintains: Outperform | $40 → $45 | $36.80 | +22.28% | 6 | Oct 27, 2025 | |
| MBX MBX Biosciences | Maintains: Outperform | $38 → $56 | $31.85 | +75.82% | 2 | Sep 24, 2025 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $51 → $85 | $29.09 | +192.20% | 2 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $6.76 | +491.72% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $40 | $234.34 | -82.93% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $3.65 | +173.97% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $1.34 | +123.88% | 2 | Mar 1, 2023 |
Relmada Therapeutics
Mar 20, 2026
Maintains: Outperform
Price Target: $10 → $19
Current: $7.04
Upside: +169.89%
Sarepta Therapeutics
Mar 13, 2026
Maintains: Outperform
Price Target: $26 → $31
Current: $16.80
Upside: +84.52%
uniQure
Mar 11, 2026
Upgrades: Outperform
Price Target: $12 → $35
Current: $24.19
Upside: +44.69%
Arcutis Biotherapeutics
Mar 2, 2026
Maintains: Outperform
Price Target: $37 → $35
Current: $20.86
Upside: +67.79%
ACADIA Pharmaceuticals
Feb 23, 2026
Upgrades: Outperform
Price Target: $29 → $35
Current: $21.10
Upside: +65.88%
Neurocrine Biosciences
Dec 12, 2025
Maintains: Neutral
Price Target: $146 → $175
Current: $156.70
Upside: +11.68%
Evolus
Dec 2, 2025
Maintains: Outperform
Price Target: $20 → $19
Current: $6.09
Upside: +211.99%
Alkermes
Oct 27, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $36.80
Upside: +22.28%
MBX Biosciences
Sep 24, 2025
Maintains: Outperform
Price Target: $38 → $56
Current: $31.85
Upside: +75.82%
Tectonic Therapeutic
May 15, 2025
Maintains: Outperform
Price Target: $51 → $85
Current: $29.09
Upside: +192.20%
May 24, 2024
Initiates: Buy
Price Target: $40
Current: $6.76
Upside: +491.72%
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $234.34
Upside: -82.93%
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $3.65
Upside: +173.97%
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $1.34
Upside: +123.88%